Clinical trials: Inflammatory Disorder
Post-ERCP Acute Pancreatitis
Rectal Indomethacin to Prevent Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
The purpose of this study is to assess whether peri-procedural administration of rectal indomethacin, compared to placebo, can reduce the incidence of post-ERCP pancreatitis.
- Trial name
- NCT01774604
- Testing
- Indomethacin
- Where
- United States
- Volunteers
- 449 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Ulcerative Colitis (UC)
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis
The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo in inducing clinical remission (per Adapted Mayo score) in participants with moderately to severely active ulcerative colitis…
- Trial name
- U-Accomplish (NCT03653026)
- Testing
- Upadacitinib
- Where
- 379 sites in United States, Argentina and 42 more
- Volunteers
- 522 people
- Sponsor
- AbbVie
COVID-19, Acute Respiratory Distress Syndrome
Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19
Ideal new treatments for Novel Coronavirus-19 (COVID-19) would help halt the progression disease in patients with mild disease prior to the need for artificial respiration (ventilators), and also provide a rescue treatment for…
- Conditions
- COVID-19, Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections
- Trial name
- SINK COVID-19 (NCT04365985)
- Testing
- Naltrexone, Ketamine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Corewell Health East
Ulcerative Colitis
A Study of Abatacept in Patients With Active Ulcerative Colitis
The purpose of this clinical research study is to learn if abatacept can improve signs and symptoms of active ulcerative colitis in patients who have not had an adequate response to other therapies.
- Trial name
- NCT00410410
- Testing
- abatacept (ABA), abatacept
- Where
- 143 sites in United States, Australia and 17 more
- Volunteers
- 591 people
- Sponsor
- Bristol-Myers Squibb
Familial Cold Autoinflammatory Syndrome
Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)
The purpose of this phase II study was to assess the safety, tolerability and efficacy of DFV890 in participants with FCAS.
- Trial name
- DFV890-FCAS (NCT04868968)
- Testing
- DFV890
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
Septic Shock
Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148
Septic shock is a potentially life-threatening condition that can result in multi-organ dysfunction syndrome (MODS) and mortality.
- Trial name
- SSAIL (NCT02317549)
- Testing
- LB1148
- Where
- 34 sites in United States, Canada
- Volunteers
- 8 people
- Sponsor
- Leading BioSciences, Inc
Cancer, Cardiac Disease
A Culturally-Based Palliative Care Tele-consult Program for Rural Southern Elders
Rural patients with life-limiting illness are at very high risk of not receiving appropriate care due to a lack of health professionals, long distances to treatment centers, and limited palliative care (PC) clinical expertise.
- Conditions
- Cancer, Cardiac Disease, Pulmonary Disease, Neuro-Degenerative Disease
- Trial name
- NCT03767517
- Testing
- Active Intervention, Usual Care
- Where
- 4 sites in United States
- Volunteers
- 209 people
- Sponsor
- University of Alabama at Birmingham
Dermatomyositis
Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)
Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis ("ProDERM study")
- Trial name
- IIM (NCT02728752)
- Testing
- Octagam 10%
- Where
- 37 sites in United States, Canada and 8 more
- Volunteers
- 95 people
- Sponsor
- Octapharma
Hemorrhoids, Hemorrhoidal Disease
War-Drill Model Guided Treatment of Hemorrhoids With Nimsai Herbal (NAJ)
This study investigated a new understanding of hemorrhoid formation and evaluated a novel systemic treatment. For 200 years, hemorrhoids were conventionally understood as isolated swollen veins.
- Trial name
- NAJ (NCT07034820)
- Testing
- Nimsai Herbal
- Where
- Turkey (Türkiye)
- Volunteers
- 300 people
- Sponsor
- Nimsai Academia
Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis
This is a randomized, double blind, placebo-controlled, parallel group multi-center study in adult participants with active moderate to severe UC.
- Trial name
- NCT01671956
- Testing
- Bertilimumab
- Where
- 6 sites in Israel
- Volunteers
- 32 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Avascular Necrosis, Osteoarthritis, Hip
Allofit® IT With HXPE in Total Hip Arthroplasty
The study design is a multi-center, prospective, non-controlled, consecutive cohort postmarket clinical follow-up study to obtain survival and outcome data on the Allofit IT Shell in combination with Longevity Liners in primary…
- Conditions
- Avascular Necrosis, Osteoarthritis, Hip, Inflammatory Arthritis, Post-Traumatic Osteoarthritis of Hip
- Trial name
- NCT03672929
- Where
- 5 sites in Austria, France and 2 more
- Volunteers
- 197 people
- Sponsor
- Zimmer Biomet
Chronic Plaque Psoriasis
Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis
Loading dose, four arm, double-blind, parallel group, placebo-controlled study comparing single and multiple doses of AIN457 to placebo in patients with a diagnosis of moderate to severe chronic plaque psoriasis.
- Trial name
- NCT00805480
- Testing
- AIN457
- Volunteers
- 130 people
- Sponsor
- Novartis Pharmaceuticals
Ulcerative Colitis
Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)
The purpose of this trial was to investigate the safety and efficacy of mesalamine 2 g extended release granules (sachet) once a day (QD) for maintenance of clinical and endoscopic remission in subjects with UC.
- Trial name
- NCT02522780
- Testing
- Mesalamine
- Where
- 96 sites in United States, Bulgaria and 9 more
- Volunteers
- 276 people
- Sponsor
- Ferring Pharmaceuticals
Colitis, Ulcerative
The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients
The purpose of this study is to determine if cobitolimod (former called Kappaproct®) is effective in the treatment of chronic active ulcerative colitis patients not responding to available therapy.
- Trial name
- COLLECT (NCT01493960)
- Testing
- Cobitolimod
- Where
- 37 sites in Czechia, France and 5 more
- Volunteers
- 131 people
- Sponsor
- InDex Pharmaceuticals
Pancreatitis, Chronic; Diabetes; Transplant
Anti-inflammatory Therapy to Improve Outcomes After TPIAT
Patients with severe chronic pancreatitis may be candidates to have their pancreas removed and their islets transplanted into the liver to reduce the risk of diabetes mellitus, a procedure called total pancreatectomy with islet…
- Trial name
- NCT02713997
- Testing
- etanercept, Alpha 1-Antitrypsin
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Minnesota
Endometritis, Wound Infection
Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection
The Cesarean Section Optimal Antibiotic Prophylaxis (C/SOAP) study is a large pragmatic multi-center randomized clinical trial designed to evaluate the comparative effectiveness and safety of azithromycin-based extended-spectrum…
- Conditions
- Endometritis, Wound Infection, Abscess, Surgical Site Infection
- Trial name
- C/SOAP (NCT01235546)
- Testing
- Azithromycin and standard of care
- Where
- 9 sites in United States
- Volunteers
- 2,013 people
- Sponsor
- Alan Tita
Crohn's Disease
Remission in Subjects With Crohn's Disease, Open Label Extension
The objectives were: (1) To demonstrate the efficacy of adalimumab in the long-term maintenance of clinical remission in participants with Crohn's disease; and (2) To delineate the long-term safety of adalimumab when administered…
- Trial name
- CLASSICII (NCT01070303)
- Testing
- Adalimumab 40 mg eow or ew
- Where
- 43 sites in United States
- Volunteers
- 177 people
- Sponsor
- Abbott
Inflammatory Bowel Disease, Glycogen Storage Disease Type Ia
Study of the Relationship Between Glycogen Storage Disease Type Ia and Inflammatory Bowel Disease
The purpose of this research study is to understand the relationship between inflammatory bowel disease (IBD) and Glycogen storage disease (GSD)type Ia.
- Trial name
- NCT01854242
- Testing
- Glycogen Storage Disease type Ia patients
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Florida
Hepatosplenic T-Cell Lymphoma
A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)
This study is designed to collect tissue samples from the biopsy specimen that was used to diagnose hepatosplenic T-cell lymphoma (HSTCL), additional patient information, and if possible, to obtain additional samples including a…
- Trial name
- NCT01804166
- Testing
- Infliximab, Golimumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Janssen Scientific Affairs, LLC
Clostridia Difficile Colitis, Clostridium; Sepsis
Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.
A new medication, Bezlotoxumab, has been approved for treatment of recurrent Clostridium difficile diarrhea by the U.S. Food and Drug Administration. The way this new medication works, is by binding the toxin produced by C.
- Trial name
- NCT03756454
- Testing
- Bezlotoxumab, Normal Saline
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Ohio State University